adalimumab · Humira
Monoclonal antibody
Biosimilars tracked: adalimumab-aacf (Idacio), adalimumab-aaty (Yuflyma), adalimumab-adaz (Hyrimoz), adalimumab-adbm (Cyltezo), adalimumab-afzb (Abrilada), adalimumab-aqvh (Yusimry), adalimumab-atto (Amjevita), adalimumab-bwwd (Hadlima), adalimumab-fkjp (Hulio), adalimumab-ryvk (Simlandi)
Evidence outlook
Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease (label: Adults and paediatric patients with moderately to severely active CD or UC who have had an...), Ulcerative Colitis, Rheumatoid Arthritis, Hidradenitis Suppurativa, Non-Infectious Uveitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (6)
- Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate.
- Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
- Treatment of rheumatoid arthritis (for use only when conventional therapies are not sufficiently effective)
- Humira is indicated for: Rheumatoid Arthritis reducing the signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Humira can be used alone or in combination with methotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs). When used as first-line treatment in recently diagnosed patients who have not been previously treated with methotrexate, Humira should be given in combination with methotrexate....
- Moderate to severely active Crohn's disease and ulcerative colitis in adults and paediatric patients
- Please refer to the product information document.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00385736 NCT00385736 · Ulcerative Colitis Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong. Registry: NCT00385736 | 3 | Proportion of Participants With Clinical Remission Per Mayo Score at Week 8 2009-04 | Higher dose (160/80/40mg): 18.5% remission vs 9.2% placebo (p=0.031). Lower dose (80/40mg): 10.0% vs 9.2% (p=0.833, not significant). | Partial signal | link ↗ |
View 7 more trials
NCT00408629 NCT00408629 · Ulcerative Colitis Randomized, quadruple-blinded, placebo-controlled, adequately powered (pre-specified sample size calculation met), with a hard clinical/endoscopic primary endpoint (Mayo score remission), and both co-primary comparisons achieved statistical significance in the favorable direction -- meeting the strict definition of 'strong'. Registry: NCT00408629 | 3 | Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52 2010-03 | Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) | Reliable signal | link ↗ |
NCT02632175 NCT02632175 · Ulcerative Colitis This open-label, single-arm extension gave adalimumab to 59 children with ulcerative colitis from an earlier trial. It assessed long-term safety and efficacy with no comparator and no formal test, so there is no result to call met or missed. Most patients had adverse events, 15 had a serious one, and most stayed in remission on the partial Mayo score. Source: CT.gov posted results. Registry: NCT02632175 | 3 | Number of Participants With Adverse Events (AEs) (From first dose of study drug until 70 days following last dose of study drug (up to 298 weeks).); Proportion of Participants Who Achieve Clinical Remission as Measured by Partial Mayo Score (PMS) (Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288); Proportion of Participants Who Achieve Clinical Response as Measured by PMS (From Study M11-290 Baseline) (Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288); Proportion of Participants Who Achieve Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission (Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288); Proportion of Participants Who Achieve PUCAI Response (From Study M11-290 Baseline) (Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288) 2025-04-08 | Open-label, single-arm long-term extension; no comparator or formal test. Any adverse event 55/59, serious 15/59; partial Mayo remission 50/59 at week 4 and 43/59 at week 24 (CT.gov posted results). | Partial signal | link ↗ |
NCT02065557 NCT02065557 · Ulcerative Colitis The trial was randomized and quadruple-blinded with a hard clinical endpoint (Mayo score remission), but its induction phase and much of its maintenance analysis compared adalimumab-treated participants to a historical/external placebo remission rate rather than to a large concurrent placebo group (the actual concurrent maintenance placebo arm had only 12 participants). Results were also inconsistent by dose: the standard-dose arm missed statistical significance at both Week 8 and Week 52, while only the high-dose and pooled-dose groups met it. A partial, dose-dependent result on a trial with this design limitation is capped at moderate rather than strong. Registry: NCT02065557 | 3 | Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period; Co-Primary Endpoint 2: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52 in Week 8 Responders Per PMS - Maintenance Period 2020-02-07 | Induction (Week 8, ITT-E, Main Study): I-SD 43.3% vs external placebo 19.83% (p=0.382, NS); I-HD 59.6% vs external placebo (p<0.001); combined I-SD+I-HD 53.2% (p<0.001). Maintenance (Week 52, mITT-E): M-PL 33.3% (n=12, descriptive only); M-SD 29.0% vs external placebo 18.37% (p=0.382, NS); M-HD 45.2% (p<0.001); combined M-SD+M-HD 37.1% (p<0.001). | Partial signal | link ↗ |
NCT02065622 NCT02065622 · Ulcerative Colitis (UC) Design is randomized, quadruple-blind, large (n=952), phase 3, with a hard endoscopy/clinical-remission primary endpoint — strong design elements — but the primary comparisons (I-SD vs I-HD induction remission, M-SD vs M-HD maintenance remission) were not significant in the Main Study population (p=0.269, p=0.069) and only marginally significant when pooled with Japan data (p=0.045), an inconsistent/borderline result; per the grading rules a well-designed trial with a null/mixed primary result is capped at moderate. Registry: NCT02065622 | 3 | Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8; Maintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 52 2019-09-05 | Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8 (Week 8): Induction (Main Study): I-SD 10.9% vs Induction (Main Study): I-HD 13.3% vs Induction (Main Study + Japan Sub-study): I-SD 11.6% vs Induction (Main Study + Japan Sub-study): I-HD 13.8%; p=0.269 (Induction (Main Study): I-SD vs Induction (Main Study): I-HD), p=0.447 (Induction (Main Study): I-SD vs Induction (Main Study): I-HD), p=0.301 (Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD), p=0.502 (Induction (Main Study + Japan Sub-study): I-SD vs Induction (Main Study + Japan Sub-study): I-HD) | Partial signal | link ↗ |
NCT00573794 NCT00573794 · Ulcerative Colitis Eligibility criteria explicitly require prior completion of two named RCTs (NCT00385736/NCT00408629), confirming this is a genuine open-label extension of prior randomized trials, despite the single-arm, unmasked, no-comparator design that would otherwise be graded weak. Registry: NCT00573794 | 3 | Partial Mayo Score: Change From Baseline Over Time (Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388); Mayo Score: Change From Baseline Over Time (Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388) 2016-12 | Partial Mayo Score: Change From Baseline Over Time (Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388): Adalimumab 40 mg EOW/EW — Baseline: 2.5 units on a scale (Standard Deviation 2.02); Change from Baseline to Week 48: -0.2 units on a scale (Standard Deviation 2.04); Change from Baseline to Week 96: -0.4 units on a scale (Standard Deviation 1.78); Change from Baseline to Week 144: -0.5 units on a scale (Standard Deviation 2.06); Change from Baseline to Week 192: -0.6 units on a scale (Standard Deviation 1.84); Change from Baseline to Week 240: -0.8 units on a scale (Standard Deviation 1.79); Change from Baseline to Week 292: -0.7 units on a scale (Standard Deviation 2.05); Change from Baseline to Week 340: -1 units on a scale (Standard Deviation 1.97); Change from Baseline to Week 388: -2 units on a scale (Standard Deviation 1) | Partial signal | link ↗ |
NCT00853099 NCT00853099 · Ulcerative Colitis Design meets 'strong' criteria (randomized, double-blind, placebo-controlled, phase 3, hard clinical/endoscopic remission endpoint, adequately powered n=274), but the record provides no statistical significance testing, and the two co-primary endpoints show discordant results -- Week 8 shows no numeric separation from placebo while Week 52 shows apparent benefit -- so per the mixed/partial-result rule this is capped at 'moderate' rather than 'strong'. Registry: NCT00853099 | 3 | Percentage of Participants With Clinical Remission at 8 Weeks (Week 8); Percentage of Participants With Clinical Remission at 52 Weeks (Week 52) 2011-05 | Percentage of Participants With Clinical Remission at 8 Weeks (Week 8): Placebo 11.5% vs Adalimumab 80 mg/40 mg 13.8% vs Adalimumab 160 mg/80 mg 10.0% | Partial signal | link ↗ |
InspirAda NCT01550965 · Ulcerative Colitis This open-label, single-arm Phase 3 study followed 463 patients with ulcerative colitis treated with adalimumab in usual clinical practice. Both hierarchically tested primaries improved from baseline: SIBDQ quality-of-life score rose by 17.4 points at week 26 (p<0.001), and UC-related care costs fell by 1,384 GBP over 6 months (p<0.001). Both primaries were met. With no control group, the changes are within-patient comparisons and cannot separate drug effect from regression or practice effects. Source: CT.gov posted results. Registry: NCT01550965 | 3 | Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score (Week 0 (baseline) and Week 26); Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Costs of UC-related Medical Care Excluding Adalimumab Costs (6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)) 2015-04 | Single-arm, week 26 vs baseline: SIBDQ total score mean change +17.4 (95% CI 16.08 to 18.73), p<0.001, n=460; UC-related medical costs (excluding adalimumab) 6 months after vs 6 months before start, mean change -1,383.81 GBP (95% CI -1,586.36 to -1,181.26), p<0.001, n=461 (CT.gov posted results). | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (115)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (58)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (103)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (29)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (111)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (55)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (9)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other TNF-alpha drugs
adalimumab-aacf (Idacio), adalimumab-aaty (Yuflyma), adalimumab-adaz (Hyrimoz), adalimumab-adbm (Cyltezo), adalimumab-afzb (Abrilada) and 17 more. Compare all 23 TNF-alpha drugs
This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Psoriatic Arthritis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Adalimumab (Humira): this drug | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | Reliable signal | NCT01860976: Proportion of ACR 20 Responders at Day 169 (Day 169): Abatacept 39.4% (95% CI 32.9 to 46) vs Placebo 22.3% (95% CI 16.7 to 27.9) | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | Reliable signal | NCT01212770: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 28.4% | Apremilast 30 mg 40.7% vs Placebo 18.3% NCT01172938: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 30.4% | Apremilast 30 mg 38.1% vs Placebo 19% | |
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | Reliable signal | NCT03896581: ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results). NCT03895203: ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results). | |
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | Weak signal | No reviewed efficacy summary in this indication | |
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | Reliable signal | NCT04908189: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002 NCT04908202: POETYK PsA-1 (NCT04908202), primary endpoint ACR20 at week 16: met, p<0.0001 | |
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | Reliable signal | NCT02376790: ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005) NCT00317499: ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001) | |
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | NCT02181673: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% phase 3 result · pivotal pending | |
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT04882098: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants NCT03162796: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (Week 24): Guselkumab 100 mg q8w 52% | Guselkumab 100 mg q4w 59.4% vs Placebo 22.2% | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Ixekizumab (Taltz) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT02349295: ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001 NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo. | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03675308: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8) | |
| Secukinumab (Cosentyx) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT04632927: HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002. NCT02404350: ACR20 at week 16: secukinumab 300 mg load 62.6%, 150 mg load 55.5%, 150 mg no load 59.5% vs placebo 27.4%; odds ratios 4.58 (95% CI 3.16 to 6.63), 3.38 (2.35 to 4.87) and 4.02 (2.78 to 5.79), all p<0.0001 (CT.gov posted results). | |
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | Partial signal | No reviewed efficacy summary in this indication | |
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03104400: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5) NCT03104374: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 56.9% (95% CI 50.2 to 63.6) | Upadacitinib 30 mg 63.8% (95% CI 57.4 to 70.1) vs Placebo 24.1% (95% CI 18.3 to 29.8) | |
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aekn (Selarsdi) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Auub (Wezlana) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Hmny (Starjemza) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Srlf (Imuldosa) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Stba (Steqeyma) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Ttwe (Pyzchiva) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Icotrokinra (Icotyde) | Phase 3 | Peptide | IL-23 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Netakimab | Phase 3 | Monoclonal antibody | IL-17 | Reliable signal | NCT03598751: ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo. | |
| Sonelokimab | Phase 3 | Antibody-derived scaffold | IL-17A/F | Partial signal | NCT06641076: Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52). NCT05640245: ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled) | |
| Tirzepatide (Zepbound) | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Vunakizumab | Phase 3 | Monoclonal antibody | IL-17 | Partial signal | NCT05055934: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively | |
| Zasocitinib | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10374 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| TQH3906 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| LPX-TI641 | Phase 1 | Small molecule | TIM receptor (Treg-expanding) | not yet graded | No reviewed efficacy summary in this indication | |
| S-4321 | Phase 1 | Multispecific antibody | PD-1 / FcγRIIb (dual) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
17 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(32 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Humira (adalimumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.